Fig. 2From: Prevalence and risk of progression of preclinical Alzheimer’s disease stages: a systematic review and meta-analysisPrevalence of pathophysiological biomarker positivity across the 2011 NIA-AA preclinical AD stages. CI confidence interval, CSF cerebrospinal fluid, PET positron emission tomographyBack to article page